Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Compugen shares jumped 204.1% to $2.22 on Tuesday.
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday.
The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07. The S&P 500 also rose, gaining, 0.54% to 4,744.58.
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday.
The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500 also rose, gaining, 0.37% to 4,736.45.
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday.
Following the market opening Monday, the Dow traded up 0.15% to 37,362.28 while the NASDAQ rose 0.14% to 14,835.17. The S&P 500 also rose, gaining, 0.29% to 4,732.84.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) shares are trading lower by 52.7% to $1.57 Monday morning after the company received a complete response letter (CRL) from the FDA regarding their application for cosibelimab, a treatment for certain types of